However, GlaxoSmithKline (GSK) is retaining rights to Entereg for postoperative ileus (POI), and the companies will continue to collaborate on the development and commercialization of Entereg for POI in the US.
GSK has also returned to Adolor rights related to Entereg for irritable bowel syndrome and non-opioid induced forms of constipation or bowel dysfunction. There have been no active development programs for these indications.
Michael Dougherty, president and CEO of Adolor, said: “Adolor maintains a portfolio of development candidates that may potentially serve this patient population, including Entereg, our combination product program, and additional earlier stage compounds.
“We intend now to explore discussions with potential partners regarding this portfolio, and to submit to the FDA for review a protocol for an additional study of Entereg in opioid bowel dysfunction under a special protocol assessment.”